At a glance
- Originator Eli Lilly and Company
- Class Anti-ischaemics; Antithrombotics; Small molecules
- Mechanism of Action Thrombin inhibitors; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Myocardial infarction in USA (Unknown route)
- 02 Feb 1996 Preclinical development for Myocardial infarction in USA (Unknown route)